cll: long-term updates on ibrutinib and idelalisib
Published 6 years ago • 2.1K plays • Length 25:09Download video MP4
Download video MP3
Similar videos
-
25:38
cll: chemotherapy and ibrutinib based regimens
-
21:42
update on btk inhibitors for cll: ibrutinib pus the new kids on the block: are they better?
-
12:59
cll: idelalisib based regimens
-
24:09
update on venetoclax for cll
-
14:12
abstract: single-agent ibrutinib 420mg induces durable responses in patients with cll
-
27:18
novel treatment options in cll
-
1:33
dr. zelenetz on treatment for patients with cll who fail on ibrutinib or idelalisib
-
20:23
cll: update on approved tkis and their use in clinical practice
-
18:36
update on pi3k inhibitors for cll: idelalisib, copanlisib, duvelisib, and umbralisib
-
1:29
dr. james on update of ibrutinib for chronic lymphocytic leukemia
-
1:16
dr. jones on long-term outcomes with ibrutinib in cll
-
29:14
ibrutinib resistance-mechanisms and options in cll
-
1:05
long-term outcomes of patients with cll treated with continuous ibrutinib
-
1:44
ibrutinib and fcr in cll irrespective of ighv mutation status
-
2:55
clinical outcomes of patients with cll receiving long-term ibrutinib in the resonate-2 study
-
11:43
2013 annual hematology meeting: lymphoma - ibrutinib & idelalisib
-
19:42
treatment options for the young cll patient with deletion 17p: do they need a different approach?
-
21:50
update on venetoclax for cll: how low can you go (mrd)?
-
21:05
cll: optimal approaches for patients with deletion 17p